Profiling $CABA:
I have been in this company for about 8 months now. I think the management is good, but way too early to tell. They are my small cap high risk play.
I have been in this company for about 8 months now. I think the management is good, but way too early to tell. They are my small cap high risk play.
1/ They are using CAAR-T to target autoimmune disorders. They use a CAAR receptor that encodes a self antigen that drives auto immune disease. The concept is the self reactive B cells should target binding to the CAAR receptor and the T cell would kill them.
2/ Based on the really low level of memory B cells in the body, it could be very difficult to clear them out. Its a high risk play, but if it works, it could be a huge opportunity.
3/ They have multiple indications, but the first one is for mPV which only accounts for about 4,000 to 5,000 patients. Many of these program have small patient populations. With the company at only $300 million market cap, it could be a 10x return should the data work out.
4/ So far the only data they have is safety data. The efficacy data is expected to read out by year end.
• • •
Missing some Tweet in this thread? You can try to
force a refresh
